<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>26255570</identifier>
<setSpec>1885-1398</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Flores-Suárez, Luis Felipe</dc:author>
<dc:author>Alba, Marco A</dc:author>
<dc:description xml:lang="en">ANCA-associated vasculitides (AAV) are chronic autoimmune diseases characterized by inflammation and destruction of small vessels. Rituximab is now licensed for use as a remission-induction agent in the treatment of these disorders. During recent years, several non-controlled studies have suggested that rituximab may be of value in maintaining disease remission in AAV. In these series, 3 techniques have been tried: "watch-and-wait", repeated cycles in fixed intervals, or administration based on proposed biomarkers. More importantly, the results of the MAINRITSAN trial showed that this anti-CD20 agent is superior to azathioprine for preventing major relapses in AAV. This review summarizes current information regarding the effectiveness, timing, dosing, duration and safety of rituximab as a valid option for remission maintenance.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Anti-neutrophil cytoplasmic antibodies</dc:subject>
<dc:subject>Microscopic polyangiitis</dc:subject>
<dc:subject>Treatment</dc:subject>
<dc:subject>Anticuerpos anticitoplasma de neutrófilo</dc:subject>
<dc:subject>Granulomatosis con poliangitis</dc:subject>
<dc:subject>Granulomatosis with polyangiitis</dc:subject>
<dc:subject>Rituximab</dc:subject>
<dc:subject>Tratamiento</dc:subject>
<dc:subject>Poliangitis microscópica</dc:subject>
<dc:subject>Maintenance</dc:subject>
<dc:subject>Mantenimiento</dc:subject>
<dc:date>2016 Jan-Feb </dc:date>
<dc:title xml:lang="en">Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?</dc:title>
<dc:publisher>Reumatologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
